persistent pain and fatigue drive reduced quality of life in treated Gaucher disease type 1: a cross-sectional analysis
Open Access
- 16 June 2026
- journal article
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Abstract
Purpose: Gaucher disease type 1 (GD1) is a multisystem lysosomal disorder in which treatment with enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) improves key clinical parameters. However, many patients continue to experience persistent symptoms that are not captured by traditional disease markers. This study evaluated the relationship between pain, fatigue, and health-related quality of life (HRQoL) among treated adults with GD1. Methods: In this cross-sectional study, adults with GD1 receiving ERT or SRT ( N = 97) completed an online survey including the 36-item Short Form Survey (SF-36), PROMIS ® Fatigue and Pain Interference Short Forms, and the Treatment Satisfaction Questionnaire for Medication©. Associations between demographic factors, treatment variables, symptoms, and HRQoL were assessed using correlation analyses, t-tests, ANOVA, and multiple regression. Results: Pain and fatigue were strong, independent predictors of both physical and mental HRQoL, with age additionally predicting physical HRQoL. Significant negative correlations were observed between pain and HRQoL (physical and mental), as well as between fatigue and HRQoL. Participants reported significantly lower HRQoL compared with U.S. population norms across 7 of 8 SF-36 domains. Conclusions: Persistent pain and fatigue represent major, under-recognized drivers of impaired quality of life in treated GD1, indicating that current therapies do not fully address the symptomatic burden of disease. These findings support routine integration of validated patient-reported outcome measures into clinical care and highlight the need for adjunctive and mechanism-based approaches to improve patient-centered outcomes.Keywords
This publication has 45 references indexed in Scilit:
- Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final resultsAmerican Journal of Hematology, 2021
- Quality of life and psychological functioning of pediatric and young adult patients with Gaucher disease, type 1American Journal of Medical Genetics Part A, 2020
- Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trialAmerican Journal of Hematology, 2018
- Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patientsAmerican Journal of Hematology, 2016
- Gaucher Disease and Bone ManifestationsCalcified Tissue International, 2014
- Long‐term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatmentJournal of Inherited Metabolic Disease, 2012
- Quality of Life of Brazilian Patients with Gaucher Disease and Fabry Disease2012
- A reappraisal of Gaucher disease—diagnosis and disease management algorithmsAmerican Journal of Hematology, 2010
- Health‐related quality of life measures in genetic disorders: An outcome variable for consideration in clinical trialsAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2009
- Quality of life related to type 1 Gaucher disease: Spanish experienceQuality of Life Research, 2005